MediWound Q4 Earnings Call Highlights

Core Insights - MediWound is expanding the development of EscharEx beyond venous leg ulcers (VLUs) to include diabetic foot ulcers (DFUs) and pressure ulcers, with plans to initiate a Phase II study in DFUs in the second half of 2026 [1][7] - The company reported a decline in revenue for 2025, primarily due to a U.S. government shutdown, but reaffirmed revenue guidance for the upcoming years [5][17] Company Developments - MediWound's CEO highlighted 2025 as a pivotal year, with significant growth drivers in place, particularly the ongoing Phase III VALUE trial for EscharEx targeting 216 patients across approximately 40 sites in the U.S. and Europe [3][4] - The company has completed an expanded manufacturing facility for NexoBrid, increasing production capacity sixfold, with commercial release expected pending regulatory clearance in the second half of 2026 [6][9] Financial Performance - For Q4 2025, MediWound reported revenue of $1.9 million, down from $5.8 million in the prior year, largely due to the U.S. government shutdown [11] - Full-year 2025 revenue was $17.0 million, a decrease from $20.2 million in 2024, with gross profit improving to $3.3 million (19.2% margin) [13][14] - The company ended 2025 with $53.6 million in cash, up from $43.6 million at the end of 2024, and used $21.4 million for operating activities during the year [16] Research and Collaborations - MediWound is collaborating with several advanced wound care companies, including B. Braun, to support the clinical development of EscharEx, particularly in the planned Phase II DFU study [8] - The company plans to conduct third-party market research alongside the pressure ulcer initiative to quantify the addressable market opportunity [7] Future Outlook - Management reaffirmed revenue guidance of $24 million to $26 million for 2026, $32 million to $35 million for 2027, and $50 million to $55 million for 2028, assuming continued support from BARDA and the U.S. Department of War [17][18] - The company has been awarded $18.2 million in non-dilutive funding from the U.S. Department of War to support the development of a room-temperature stable formulation for military applications [18]